Strs Ohio Sells 3,447 Shares of Thermo Fisher Scientific Inc. $TMO

Strs Ohio decreased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 248,077 shares of the medical research company’s stock after selling 3,447 shares during the period. Thermo Fisher Scientific comprises about 0.5% of Strs Ohio’s investment portfolio, making the stock its 26th biggest position. Strs Ohio’s holdings in Thermo Fisher Scientific were worth $143,748,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the stock. Pines Wealth Management LLC increased its holdings in shares of Thermo Fisher Scientific by 16.1% in the 4th quarter. Pines Wealth Management LLC now owns 3,239 shares of the medical research company’s stock worth $1,877,000 after buying an additional 449 shares during the last quarter. Sandro Wealth Management LLC bought a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at $2,089,000. Artemis Investment Management LLP grew its holdings in shares of Thermo Fisher Scientific by 2.1% during the 4th quarter. Artemis Investment Management LLP now owns 62,173 shares of the medical research company’s stock valued at $36,026,000 after purchasing an additional 1,300 shares during the last quarter. SevenBridge Financial Group LLC grew its holdings in shares of Thermo Fisher Scientific by 1.4% during the 4th quarter. SevenBridge Financial Group LLC now owns 6,117 shares of the medical research company’s stock valued at $3,833,000 after purchasing an additional 83 shares during the last quarter. Finally, Ashton Thomas Securities LLC grew its holdings in shares of Thermo Fisher Scientific by 5.9% during the 4th quarter. Ashton Thomas Securities LLC now owns 5,955 shares of the medical research company’s stock valued at $3,456,000 after purchasing an additional 334 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 5,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at $63,499,170. This trade represents a 3.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the transaction, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 5,800 shares of company stock worth $2,963,544 in the last ninety days. Insiders own 0.33% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on TMO shares. UBS Group reaffirmed a “neutral” rating and set a $615.00 target price on shares of Thermo Fisher Scientific in a report on Friday, January 30th. Morgan Stanley reissued an “overweight” rating and issued a $620.00 price target on shares of Thermo Fisher Scientific in a report on Monday. Barclays cut their price target on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a report on Tuesday, April 14th. TD Cowen cut their price target on shares of Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating on the stock in a report on Friday, January 30th. Finally, DZ Bank started coverage on shares of Thermo Fisher Scientific in a report on Friday, March 27th. They issued a “buy” rating and a $610.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $623.05.

Thermo Fisher Scientific Trading Down 2.0%

Shares of TMO opened at $469.39 on Friday. The firm’s 50-day moving average price is $496.11 and its 200-day moving average price is $547.71. The firm has a market capitalization of $174.43 billion, a price-to-earnings ratio of 25.80, a PEG ratio of 2.12 and a beta of 0.88. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. The firm had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 24.85 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th were paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend was Friday, March 13th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. Thermo Fisher Scientific’s payout ratio is presently 10.34%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.